尿路上皮がん治療薬の世界市場レポート 2024年

尿路上皮がん治療薬の市場規模は近年急激に拡大しています。2023年の23億4,000万米ドルから2024年には28億4,000万米ドルへと、CAGR21.2％で拡大します。この期間の増加は、認知度の向上と早期発見の促進に重点を置いた取り組み、医師向けの教育プログラム、患者支援団体による支援、標準治療の進歩、バイオマーカーの同定によるものです。

化学療法に対する需要の高まりが、尿路上皮がん治療薬市場の成長を促進します。化学療法は、血流を介して全身を循環する全身治療であり、遠隔部位に転移した可能性のあるがん細胞に対して有効であることが証明されています。尿路上皮がん管理における化学療法の適用には、がん細胞の増殖抑制、転移性疾患の治療、急速に分裂する細胞の標的化、症状緩和と患者のQOL向上のための緩和ケアなどが含まれます。ヘルスケアITニュースが2022年2月に報じたように、国際がん対策連合（UICC）によると、がん化学療法の需要は2040年までに1,000万人から1,500万人に増加すると予想されています。化学療法の需要増加は、尿路上皮がん治療におけるその重要な役割を強調し、尿路上皮がん治療薬市場の成長に寄与しています。

老人人口の増加は尿路上皮がん治療薬市場の重要な促進要因です。老年人口を構成する65歳以上の成人は、高齢に伴う免疫力の低下により、さまざまな病気にかかりやすくなっています。尿路上皮がんのリスクは加齢とともに高まり、尿路上皮がん治療薬による治療が必要となります。世界保健機関（WHO）が提供した2022年10月のデータによると、世界全体では2030年までに6人に1人が60歳以上になり、2050年までにこの年齢層の人口は21億人に倍増すると予測されています。同様に、英国議会の下院図書館によると、2021年6月のデータでは、英国の高齢者人口は2043年までに総人口の24％（1740万人）を占めるとされています。高齢者人口の増加により、この層に対する効果的な治療法のニーズが高まり、尿路上皮がん治療薬市場の牽引役となることが期待されます。

2023年の尿路上皮がん治療薬市場シェアでは、北米が最大地域でした。アジア太平洋は予測期間中に最も急成長する地域となる見込みです。尿路上皮がん治療薬市場レポートの対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の尿路上皮がん治療薬市場促進要因と抑制要因
  • 市場の促進要因
  • 市場の抑制要因
• 世界の尿路上皮がん治療薬の市場規模実績と成長、2018年～2023年
• 世界の尿路上皮がん治療薬市場規模と成長予測、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の尿路上皮がん治療薬市場、タイプ別セグメンテーション、実績および予測、2018年～2023年、2023年～2028年、2033年
• 尿路上皮がん
• 扁平上皮がん
• 腺がん
• 世界の尿路上皮がん治療薬市場、治療別セグメンテーション、実績および予測、2018年～2023年、2023年～2028年、2033年
• 免疫療法
• 化学療法
• 保存療法
• 世界の尿路上皮がん治療薬市場、流通チャネル別セグメンテーション、実績および予測、2018年～2023年、2023年～2028年、2033年
• 病院薬局
• 専門クリニック
• がん研究所
• 外来手術センター

第7章 地域および国の分析

• 世界の尿路上皮がん治療薬市場、地域別、実績および予測、2018年～2023年、2023年～2028年、2033年
• 世界の尿路上皮がん治療薬市場、国別、実績および予測、2018年～2023年、2023年～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 尿路上皮がん治療薬市場の競合情勢
• 尿路上皮がん治療薬市場の企業プロファイル
  • F Hoffmann La Roche AG
  • The Bristol-Myers Squibb Company
  • Merck &Co Inc.
  • Pfizer Inc.
  • Genentech Inc

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

Urothelial Cancer Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on urothelial cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for urothelial cancer drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The urothelial cancer drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Type: Urothelial Carcinoma; Squamous Cell Carcinoma; Adenocarcinoma
• 2) By Treatment: Immunotherapy; Chemotherapy; Preservation Therapy
• 3) By Distribution Channel: Hospital Pharmacies; Specialty Clinics; Cancer Institutes; Ambulatory Surgical Centers
• Companies Mentioned: F Hoffmann La Roche AG; The Bristol-Myers Squibb Company; Merck & Co Inc.; Pfizer Inc.; Genentech Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Urothelial cancer drugs encompass medications and therapies designed to target and treat cancer associated with urothelial cells lining the urethra, bladder, ureters, and renal pelvis. These treatments aim to eliminate cancerous cells and offer non-vesical chemotherapy options. They are primarily utilized for both prevention and treatment of urothelial cancer.

The main types of urothelial cancer include urothelial carcinoma, squamous cell carcinoma, and adenocarcinoma. Urothelial carcinoma specifically addresses epithelial tissue tumors, referring to transitional cell cancer occurring near epithelial tissues. Urothelial cancer drugs typically encompass treatment approaches such as immunotherapy, chemotherapy, and preservation therapy, all tailored for managing urothelial cancer. These drugs are distributed through various channels including hospital pharmacies, specialty clinics, cancer institutes, and ambulatory surgical centers.

The urothelial cancer drugs market research report is one of a series of new reports from The Business Research Company that provides urothelial cancer drugs market statistics, including urothelial cancer drugs industry global market size, regional shares, competitors with a urothelial cancer drugs market share, detailed urothelial cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the urothelial cancer drugs industry. This urothelial cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The urothelial cancer drugs market size has grown exponentially in recent years. It will grow from $2.34 billion in 2023 to $2.84 billion in 2024 at a compound annual growth rate (CAGR) of 21.2%. The increase during the historical period can be credited to initiatives focused on raising awareness and promoting early detection, educational programs for physicians, support from patient advocacy groups, the advancement of standard care practices, and the identification of biomarkers.

The urothelial cancer drugs market size is expected to see exponential growth in the next few years. It will grow to $5.92 billion in 2028 at a compound annual growth rate (CAGR) of 20.2%. The projected growth during the forecast period can be linked to progress in diagnostic imaging, the integration of artificial intelligence in drug development, a shift towards patient-centered care, increased investment in research and development, and regulatory modifications. Key trends anticipated in this period involve advancements in imaging technologies, the emphasis on patient-centric care, changes in healthcare reimbursement structures, the utilization of genomic profiling, and the evolution of regulatory frameworks.

The increasing prevalence of urothelial cancer is anticipated to drive the urothelial cancer drug market. Urothelial cancer, associated with urothelial cells lining various organs, necessitates novel drugs and therapies to address the growing incidence of the disease and reduce fatalities. For instance, data from January 2023 provided by the American Cancer Society Inc., a US-based health organization, reveals that approximately 62,420 men and 19,870 women are diagnosed with bladder cancer out of 82,290 new cases. The reported figures also include 16,710 deaths due to bladder cancer, with 4,550 cases among women and 12,160 among men. The rising prevalence of urothelial cancer underscores the need for advancements in urothelial cancer drugs and therapies, driving the market forward.

The increasing demand for chemotherapy is set to propel the growth of the urothelial cancer drugs market. Chemotherapy, a systemic treatment circulating throughout the body via the bloodstream, proves effective against cancer cells that may have spread to distant sites. Its application in urothelial cancer management includes inhibiting cancer cell growth, treating metastatic disease, targeting rapidly dividing cells, and providing palliative care to relieve symptoms and improve patients' quality of life. As reported in February 2022 by Healthcare IT News, the demand for cancer chemotherapy is expected to rise from 10 million to 15 million by 2040, according to the Union for International Cancer Control (UICC). The increasing demand for chemotherapy underscores its crucial role in urothelial cancer treatment, contributing to the growth of the urothelial cancer drugs market.

The rising prevalence of the geriatric population is identified as a significant driver for the urothelial cancer drugs market. Adults aged 65 and older, constituting the geriatric population, are more susceptible to various diseases due to lowered immunity associated with advanced age. The risk of urothelial cancer increases with age, necessitating urothelial cancer drugs for treatment. According to data from October 2022 provided by the World Health Organization, globally, 1 in 6 people will be 60 or older by 2030, and the number of individuals in this age group is expected to double to 2.1 billion by 2050. Similarly, data from June 2021, according to the UK Parliament's House of Commons Library, indicates that the senior population in the UK will comprise 24% of the total population (17.4 million people) by 2043. The rising prevalence of the geriatric population is expected to drive the urothelial cancer drug market as the need for effective treatments for this demographic grows.

The urothelial cancer drug market is witnessing a significant trend towards the development of novel combination therapies. Combination therapy involves the use of two or more therapeutic agents for the treatment of a condition. Major players in the urothelial cancer drug market are strategically focusing on creating combination therapies to strengthen their position. Combining immunotherapy with targeted drugs is particularly attractive in cancer management as it aims to reduce the emergence of resistance and improve treatment response. For instance, a notable development in July 2022 involved the United States Food and Drug Administration (FDA) accepting the biologics license application (BLA) for an IL-15 superagonist, ImmunityBio's N-803, in combination with Bacillus Calmette-Guerin (BCG) vaccine for bladder cancer. This combination therapy is designed to be delivered directly to induce natural killer cells and T cells in the bladder, representing an innovative approach in urothelial cancer treatment.

Major companies in the urothelial cancer drugs market are also prioritizing product approvals for combination therapies to drive revenues. One such example is the combination of padcev with Keytruda, a product approved by Astellas Pharma Inc., a Japan-based pharmaceutical company. In April 2023, the FDA granted approval for padcev with Keytruda for the treatment of metastatic urothelial cancer. This combination therapy is recommended as the initial line of treatment when cisplatin-containing chemotherapy is not an option for certain patients with locally advanced or metastatic urothelial carcinoma. Clinical studies have shown that the combination of padcev with Keytruda significantly enhances overall survival and progression-free survival in patients with advanced bladder cancer.

Major companies operating in the urothelial cancer drugs market report are F Hoffmann La Roche AG, The Bristol-Myers Squibb Company, Merck & Co Inc., Pfizer Inc., Genentech Inc., GSK PLC, UroGen Pharma Inc., Johnson & Johnson Inc., Astellas Pharma Inc., Sesen Bio Inc., Gilead Sciences Inc., Seagen Inc., Eisai Co. Ltd., Agensys Inc., AstraZeneca, Novartis AG, GlaxoSmithKline PLC, Sanofi SA, Janssen Pharmaceuticals Inc., Seattle Genetics Inc., Eli Lilly and Company, Bayer AG, AbbVie Inc., Exelixis Inc., Ipsen Biopharmaceuticals Inc., Millennium Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Kyowa Kirin Co. Ltd., Spectrum Pharmaceuticals Inc., Zydus Lifesciences Ltd.

North America was the largest region in the urothelial cancer drugs market share in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the urothelial cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the urothelial cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The urothelial cancer drugs market consists of sales of targeted therapy urothelial cancer drugs and chemo therapy urothelial cancer drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Urothelial Cancer Drugs Market Characteristics

3. Urothelial Cancer Drugs Market Trends And Strategies

4. Urothelial Cancer Drugs Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Urothelial Cancer Drugs Market Size and Growth

• 5.1. Global Urothelial Cancer Drugs Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Urothelial Cancer Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Urothelial Cancer Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Urothelial Cancer Drugs Market Segmentation

• 6.1. Global Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Urothelial Carcinoma
• Squamous Cell Carcinoma
• Adenocarcinoma
• 6.2. Global Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Immunotherapy
• Chemotherapy
• Preservation Therapy
• 6.3. Global Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacies
• Specialty Clinics
• Cancer Institutes
• Ambulatory Surgical Centers

7. Urothelial Cancer Drugs Market Regional And Country Analysis

• 7.1. Global Urothelial Cancer Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Urothelial Cancer Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Urothelial Cancer Drugs Market

• 8.1. Asia-Pacific Urothelial Cancer Drugs Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Urothelial Cancer Drugs Market

• 9.1. China Urothelial Cancer Drugs Market Overview
• 9.2. China Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Urothelial Cancer Drugs Market

• 10.1. India Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Urothelial Cancer Drugs Market

• 11.1. Japan Urothelial Cancer Drugs Market Overview
• 11.2. Japan Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Urothelial Cancer Drugs Market

• 12.1. Australia Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Urothelial Cancer Drugs Market

• 13.1. Indonesia Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Urothelial Cancer Drugs Market

• 14.1. South Korea Urothelial Cancer Drugs Market Overview
• 14.2. South Korea Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Urothelial Cancer Drugs Market

• 15.1. Western Europe Urothelial Cancer Drugs Market Overview
• 15.2. Western Europe Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Urothelial Cancer Drugs Market

• 16.1. UK Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Urothelial Cancer Drugs Market

• 17.1. Germany Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Urothelial Cancer Drugs Market

• 18.1. France Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Urothelial Cancer Drugs Market

• 19.1. Italy Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Urothelial Cancer Drugs Market

• 20.1. Spain Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Urothelial Cancer Drugs Market

• 21.1. Eastern Europe Urothelial Cancer Drugs Market Overview
• 21.2. Eastern Europe Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Urothelial Cancer Drugs Market

• 22.1. Russia Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Urothelial Cancer Drugs Market

• 23.1. North America Urothelial Cancer Drugs Market Overview
• 23.2. North America Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Urothelial Cancer Drugs Market

• 24.1. USA Urothelial Cancer Drugs Market Overview
• 24.2. USA Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Urothelial Cancer Drugs Market

• 25.1. Canada Urothelial Cancer Drugs Market Overview
• 25.2. Canada Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Urothelial Cancer Drugs Market

• 26.1. South America Urothelial Cancer Drugs Market Overview
• 26.2. South America Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Urothelial Cancer Drugs Market

• 27.1. Brazil Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Urothelial Cancer Drugs Market

• 28.1. Middle East Urothelial Cancer Drugs Market Overview
• 28.2. Middle East Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Urothelial Cancer Drugs Market

• 29.1. Africa Urothelial Cancer Drugs Market Overview
• 29.2. Africa Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Urothelial Cancer Drugs Market Competitive Landscape And Company Profiles

• 30.1. Urothelial Cancer Drugs Market Competitive Landscape
• 30.2. Urothelial Cancer Drugs Market Company Profiles
  • 30.2.1. F Hoffmann La Roche AG
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. The Bristol-Myers Squibb Company
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Merck & Co Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Pfizer Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Genentech Inc
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Urothelial Cancer Drugs Market Competitive Benchmarking

32. Global Urothelial Cancer Drugs Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Urothelial Cancer Drugs Market

34. Urothelial Cancer Drugs Market Future Outlook and Potential Analysis

• 34.1 Urothelial Cancer Drugs Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Urothelial Cancer Drugs Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Urothelial Cancer Drugs Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer